Tesamorelin in New Zealand: Research Overview and Availability

The short answer

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). In the published literature it is described as acting on the pituitary gland. Abroad it is known under brand names such as Egrifta and Egrifta SV, approved by the United States Food and Drug Administration for a specific HIV-associated condition. In New Zealand it is not a household over-the-counter product, and material offered for laboratory study is supplied strictly as a research-use-only compound.

This page summarises publicly available information for educational purposes. It does not describe human use, dosing, or outcomes, and nothing here should be read as encouragement to administer tesamorelin to people or animals.

What is tesamorelin?

Tesamorelin is a stabilised synthetic peptide based on human growth-hormone-releasing hormone. In scientific writing it is classified as a GHRH analogue. The naturally occurring hormone is broken down very quickly in the body, and the synthetic analogue was designed to be more stable so it can be studied more readily in controlled settings.

How it is commonly described in the literature

• A synthetic analogue of growth-hormone-releasing hormone (GHRH).
• A peptide, meaning a short chain of amino acids.
• A compound originally developed and studied in a clinical research programme overseas.
• A reference material used in laboratory and analytical research settings.

Because tesamorelin is a peptide, it is typically handled and stored under the same careful conditions as other research peptides, with attention to temperature, reconstitution practices, and documentation.

How it is described to work (mechanism from literature only)

Published pharmacology describes tesamorelin as binding to GHRH receptors on the pituitary gland and prompting the gland to release the body's own growth hormone, which in turn can influence levels of insulin-like growth factor 1 (IGF-1). This is a description of a biological mechanism reported in research, not a claim about any benefit, result, or suitability for any person.

Regulatory status in New Zealand (ARTG and scheduling)

The New Zealand Register of Therapeutic Goods (ARTG) is the register of therapeutic goods that may be lawfully supplied in New Zealand. Based on publicly available information, tesamorelin is not an approved or registered medicine in New Zealand under a brand such as Egrifta, and we could not confirm an active ARTG entry for it. Where a substance is not included in the ARTG it is generally described by the Therapeutic Goods Administration as an unapproved therapeutic good.

Peptides of this kind are generally handled as prescription-category substances rather than consumer products. We were not able to independently verify a specific entry or schedule number in the current Poisons Standard for tesamorelin, so we state the position neutrally rather than asserting a schedule. Anyone needing a definitive answer should check the current Poisons Standard on the Federal Register of Legislation and the ARTG search tool on the TGA website, as these are the authoritative sources and can change over time.

Approved medicine abroad versus research compound

It helps to separate two very different things. One is an approved prescription medicine, manufactured, labelled, and regulated for a defined medical indication. The other is a reference compound supplied purely for laboratory research, with no therapeutic claims and not intended for administration to humans or animals.

The distinction in plain terms

• Abroad, tesamorelin (for example Egrifta and Egrifta SV) is an approved prescription medicine in the United States for a specific HIV-associated indication involving excess visceral abdominal fat, first approved in 2010 with a later reformulation.
• That overseas approval does not make the compound an approved medicine in New Zealand.
• A research-use-only compound is supplied for in-vitro and laboratory study only and carries no approval, indication, or therapeutic claim.

Synergy Bio supplies tesamorelin only as a research-use-only compound. It is not sold as a medicine, is not a substitute for any approved product, and is not intended for human or veterinary use.

WADA and sport status

The World Anti-Doping Agency (WADA) Prohibited List includes growth-hormone-releasing factors within its peptide hormones and growth factors category. Recent versions of the list name GHRH and its analogues, and specifically list tesamorelin alongside compounds such as CJC-1295 and sermorelin. This class is prohibited at all times, both in and out of competition.

Athletes and support personnel subject to anti-doping rules should treat tesamorelin as a prohibited substance and confirm the position on the current WADA list, as the list is updated periodically. This paragraph is informational and is not advice about participation in sport.

What research-use-only actually means

Research-use-only is not a marketing phrase. It describes the intended purpose and the legal boundaries of how a compound is supplied. A research-use-only material is intended for laboratory investigation by appropriately equipped and qualified researchers, and it is not supplied for consumption, injection, or any form of human or animal use.

Practical implications of research-use-only supply

• No therapeutic, performance, or cosmetic claims are made or implied.
• No dosing information, protocols, or usage instructions are provided.
• The material is intended for in-vitro and laboratory research contexts.
• Buyers are responsible for understanding and complying with all applicable laws.

Research-use-only means exactly that: a reference compound for the laboratory, with no medical indication, no dosing, and no promise of any result.

Availability and quality considerations

When a compound is handled for research, documentation and consistency matter. Quality-focused suppliers provide a Certificate of Analysis (CoA) and support third-party analytical testing so that researchers can review identity and purity data rather than taking a label at face value.

What to look for in a research-grade supply

• A Certificate of Analysis (CoA) available for the batch.
• Independent or third-party analytical testing to verify identity and purity.
• Clear research-use-only labelling with no therapeutic claims.
• Transparent storage, handling, and reconstitution guidance for laboratory conditions.
• Responsive support and clear provenance for each batch.

Synergy Bio provides tesamorelin as a research-use-only compound with a Certificate of Analysis and third-party testing, and ships within New Zealand. This reflects the way reference materials are documented for laboratory work and is not a therapeutic or outcome claim.

Buying considerations in New Zealand

Anyone sourcing research peptides in New Zealand should think first about legality, documentation, and intended purpose. Because tesamorelin is not an approved medicine here and is handled as a prescription-category substance, it is important to understand the research-use-only boundary and to keep within applicable laws.

Sensible questions to ask before purchasing

• Is the material clearly supplied as research-use-only, with no therapeutic claims?
• Is a current Certificate of Analysis available for the batch?
• Is third-party testing offered to confirm identity and purity?
• Does the supplier ship within New Zealand with clear handling guidance?
• Do you understand your own legal obligations and the current regulatory position?

Frequently asked questions